Short-Term versus Sustained Response to Interferon Therapy: Effect on Histology

Digestive Diseases and Sciences

Volumn 41, Issue 12 SUPPL., 1996, Pages

  Reichard, Olle ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Chronic infection; Hepatitis C; Interferon ; Liver histology; Treatment outcome

Indexed keywords

ALPHA2B INTERFERON;

CONFERENCE PAPER; DRUG EFFICACY; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LONG TERM EXPOSURE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030467125     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G: Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 16:273-281, 1992
2. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T: Natural course of chronic hepatitis C. Am J Gastroenterol 88:240-243, 1993
3. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466, 1995
4. Tine F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 13:192-199, 1991
5. 2b for 60 weeks. Hepatology 19:280-285, 1994
6. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
7. Shindo M, Di Bisceglie AM, Cheung L, Shih WK, Cristiano K, Feinstone SM, Hoofnagle JH: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115:700-704, 1991
8. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J: Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 17:390-346, 1993
9. Schlichting P, Hølund B, Poulsen H: Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 18:27-32, 1983
10. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko G: The pathology of hepatitis C. Hepatology 15:567-571, 1992
11. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 15:572-577, 1992
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520, 1994
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435, 1981
14. Reichard O, Glaumann H, Norkrans G, Wejstål R, Frydén A, Schvarcz R, Weiland O: Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 14:169-174, 1994
15. The French METAVIR Cooperative Study Group: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15-20, 1994
16. Shindo M, Arai K, Sokawa Y, Okuno T: Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α-therapy. Ann Intern Med 122:586-591, 1995
17. Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 29:474-479, 1994
18. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 21:291-297, 1995
19. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H: Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 22:426-431, 1995
20. Weiland O, Zhang Y-Y, Widell A: Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 25:25-30, 1993
21. Reichard O, Glaumann H, Weiland O: Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response. Scand J Infect Dis 26:383-389, 1994
22. Reichard O, Glaumann H, Frydén A, Norkrans G, Schvarcz R, Sönnerborg A, Yun Z-B, Weiland O: Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 21:918-922, 1995